|To: scaram(o)uche who wrote (117)||12/6/2002 12:35:55 PM|
|Dr. David C. U'Prichard, 53............................................................. 1999 2003|
Dr. David C. U'Prichard joined us in September 1999 as our Chief Executive
Officer and a member of our Board of Directors. From August 1997 to February
1999, Dr. U'Prichard served as President of Research and Development at
One of biotech's worst CEOs, IMO. And in the opinion of others.
So, Dr. U'Prichard, I have always been a fan of "doubling down" in good companies. Do you have one OUNCE of reason in you, one ounce of RATIONALE, to convince shareholders that you are acting in their best interest? You are, IMO, doing one heck of a shitty job despite that huge salary. Defend yourself.
Why don't you give this last year's salary back to the company? Show some class.
Any number of SI biofreaks could do a better job, mailing in instructions.
|RecommendKeepReplyMark as Last Read|
|To: scaram(o)uche who wrote (122)||1/16/2003 8:26:03 AM|
|Johnson&Johnson to Acquire 3-Dimensional Pharmaceuticals, Inc. Acquisition to Expand Johnson&Johnson's Pharmaceutical Research and Development Capability |
PR Newswire, Thursday, January 16, 2003 at 08:01
NEW BRUNSWICK, N.J. and YARDLEY, Pa., Jan 16, 2003 /PRNewswire-FirstCall via COMTEX/ -- Johnson&Johnson and 3-Dimensional Pharmaceuticals, Inc. (Nasdaq: DDDP), 3DP, today announced that they signed a definitive agreement under which Johnson&Johnson will acquire 3DP, a company with a technology platform focused on the discovery and development of therapeutic small molecules.
Under the terms of the agreement, 3DP shareholders will receive $5.74 for each outstanding 3DP share. The value of the transaction as of the anticipated closing date is estimated to be approximately $88 million, net of cash. The transaction is expected to close during the first half of the second quarter of 2003, subject to regulatory approvals and other closing conditions. The acquisition is not expected to have a material impact on revenues or earnings of Johnson&Johnson."3DP will provide a good strategic fit with our pharmaceutical discovery and development capabilities,"said Dr. Per Peterson, Chairman, Research&Development for the pharmaceuticals group of Johnson&Johnson."The addition of 3DP's expertise and proprietary drug discovery technology will expand and enhance our own new pharmaceutical development efforts."Headquartered in Yardley, Pennsylvania, 3DP applies the latest techniques in high throughput screening, combinatorial chemistry, X-ray crystallography, structure-based drug design and cheminformatics to discover and develop new drugs in the areas of oncology, inflammation, metabolic and cardiovascular diseases. 3DP's proprietary drug discovery technology, known as DiscoverWorks(R), is intended to increase the productivity of the drug discovery process and enables scientists to design improved characteristics into lead drug candidates.
3DP has drug discovery and development programs focusing on potential new drugs in early stage development for the treatment of cardiovascular disorders, oncology and inflammation. 3DP has research operations in Exton, Pennsylvania and Cranbury, New Jersey."The merger with Johnson&Johnson is a wonderful opportunity for 3DP to fully realize its drug discovery mission and to exploit its technologies on a broad scale,"said Dr. David U'Prichard, Chief Executive Officer, 3DP."Johnson&Johnson will provide an outstanding environment for our employees, and we look forward to working closely with and contributing to the success of their worldwide research and development."Johnson&Johnson, with approximately 108,300 employees, is the world's most comprehensive and broadly based manufacturer of health care products, as well as a provider of related services, for the consumer, pharmaceutical, and medical devices and diagnostics markets. Johnson&Johnson has 198 operating companies in 54 countries around the world, selling products in more than 175 countries.
3DP (http://www.3dp.com), which has about 200 employees, is dedicated to small molecule drug discovery and development. 3DP's proprietary platform, DiscoverWorks(R), has the potential to produce drug candidates suitable for faster development, with fewer resources and a higher probability of success than using conventional drug discovery methods.
(In connection with the above-described transactions, 3DP intends to file a proxy statement and other materials with the Securities and Exchange Commission. Security holders are urged to read the proxy statement and these other materials when they become available because they will contain important information. Security holders may obtain a free copy of the proxy statement and these other materials when they become available, as well as other materials filed with the Securities and Exchange Commission concerning 3DP at the Securities and Exchange Commission web site at sec.gov. Security holders of 3DP may also obtain for free the proxy statement and other documents filed by 3DP with the Securities and Exchange Commission in connection with the above-described transactions by directing a request to 3DP at 1020 Stony Hill Road, Yardley, PA 19067; Attention: Investor Relations.
3DP and its directors and executive officers may be deemed to be participants in the solicitation of proxies from 3DP stockholders with respect to the merger. Information regarding these directors and executive officers and their ownership of 3DP common stock is contained in the proxy statement for 3DP's 2002 annual meeting of stockholders. Additional information regarding these directors and executive officers and their interests will be included in the proxy statement.
|RecommendKeepReplyMark as Last ReadRead Replies (1)|
|To: mopgcw who wrote (125)||1/16/2003 11:44:42 AM|
|Pretty sucky, overall.|
Perhaps JNJ doesn't mention the potential of their molecules for a reason? In the history of biotech, there's never been a lousier partner than JNJ. For all we know, they've sand bagged Centocor.
The upside? Scratch one more management team that didn't have a concept of the breadth of the job that needed doing. They did the job, as they conceived of it, pretty well. But that's not enough.
Silly decision to fill the pipe with a molecule that needed so much preclinical, and a molecule that didn't fit the infrastructure, at that.
|RecommendKeepReplyMark as Last ReadRead Replies (1)|